Curis to Receive Technology Leadership Award
Wednesday September 24, 9:08 am ET
Citation for novel approach to the development of new therapeutics
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 24, 2003--Curis, Inc. (NASDAQ: CRIS - News) today announced that it will receive the Technical Insights' 2003 Technology Leadership Award in the field of genetic technology at the "Excellence in Emerging Technologies" awards banquet being held this evening at the Hyatt Harborside hotel in Boston, MA. This award, sponsored by Frost and Sullivan, is bestowed upon a company that has pioneered the development and introduction of an innovative technology into the market.
The Award citation states that Curis has developed "a variety of molecular biological techniques to focus on the cell signaling pathways involved in development of an individual to stimulate or inhibit proliferation of specific cells in the body to treat very diverse diseases. The effort has succeeded in generating a number of promising clinical candidates and is likely to generate more."
Daniel Passeri, Curis' President and Chief Executive Officer said, "Curis is honored to have received this award. We are very pleased that the hard work and significant effort of the employees of Curis has been recognized in this manner. We thank the sponsors for that recognition."
About Curis, Inc.
Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of kidney disease, neurological disorders, cancer, and alopecia (hair loss). For more information, please visit the Curis web site at www.curis.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning Curis' or management's intentions, plans, expectations or predictions of future events are forward-looking statements. Such statements may contain the words "believes", "expects", "anticipates", "plans", "estimates" or similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those indicated by such forward-looking statements. Actual results can be affected by, among other things, uncertainties relating to product development, clinical trials, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, changes in or an inability to execute Curis' realigned business strategy and other risk factors identified in Curis' most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release.
Contact:
Curis, Inc., Cambridge
Christopher U. Missling, Ph.D., 617-503-6587
Marc F. Charette, Ph.D., 617-503-6629
Source: Curis Inc. |
